A recently published follow-up study of the first-line pembrolizumab and pembrolizumab-chemotherapy KEYNOTE-048 trial "continued to demonstrate overall survival benefit compared with cetuximab-chemotherapy" in head and neck cancer patients. A 4-year follow-up period noted a survival plateau of 20% for patients administered pembrolizumab alone, and a 30% survival rate for those patients receiving a pembrolizumab-chemotherapy combination. However, study authors did observe more favourable side effects in patients receive pembrolizumab alone without additional chemotherapy.
To read more about this study, click here.
Sources mentioned:
Harrington KJ, Burtness B, Greil R, et al. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. JCO; Published online 11 October 2022. DOI: 10.1200/JCO.21.02508
Ho AL. Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. JCO; Published online 12 October 2022. DOI: 10.1200/JCO.22.01408
No comments:
Post a Comment